hepatitis%20-%20viral%20(pediatric)
HEPATITIS - VIRAL (PEDIATRIC)
The majority of acute viral hepatitis infections are asymptomatic or they can cause an anicteric illness that may not be diagnosed as hepatitis.
Hepatitis A generally causes minor illness in childhood with >80% of infections being asymptomatic. Jaundice and intestinal symptoms usually resolve 2-3 weeks after onset. A patient is infectious 1-2 weeks prior to the clinical illness.
Hepatitis B, C, & D may be symptomatic depending on the mode and time of transmission.
Hepatitis A is predominantly transmitted through oral-fecal by person-person direct transmission and contaminated material or food.
Hepatitis B is transmitted perinatal, horizontal spread, percutaneous, sexual, close person-to-person contact.
Majority of hepatitis C infections are identified in children with repeated exposure to blood products.
Hepatitis D is route of transmission is through sexual, percutaneous especially IV drug use.
Hepatitis E is transmitted primarily through contaminated drinking water and oral-fecal transmission.

Hepatitis - Viral (Pediatric) Drug Information

Drug Information

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Primary humoral immunodeficiency. Idiopathic thrombocytopenic purpura. Chronic inflammatory demyelinating poly...

Indication: Active immunisation against HAV infection in subjects at risk of exposure to HAV.

Indication: HIV infection.

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Non-immune adult & childn ≥1 yr at risk of both hepatitis A & B infection.

Indication: 100 mg: Chronic hepatitis B & evidence of HBV replication. 150 mg: In combination w/ other antiretroviral ...

Indication: Chronic hepatitis B & evidence of HBV replication in patients ≥16 yr.

2  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).